Diagnostic Significance of Measuring Vascular Endothelial Growth Factor for the Differentiation between Malignant and Tuberculous Pleural Effusion

Kim, Hak-Ryul; Kim, Byoung-Ryun; Park, Raekil; Yoon, Kwon‐Ha; Jeong, Eun Taik; Hwang, Ki-Eun

doi:10.1620/tjem.242.137

Cited by 9 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of these previous studies were performed in patients with acute pulmonary diseases such as acute lung injury, acute respiratory distress syndrome, community-acquired pneumonia, pulmonary embolism, lung cancer, and pleural effusion. 25 – 32 There are only two studies in stable lung diseases, sarcoidosis and OSA. 33 , 34 These studies reported higher endocan levels in sarcoidosis and OSA.…”

Section: Discussionmentioning

confidence: 99%

Serum endocan levels in patients with stable COPD

Pıhtılı

Bingöl

Kıyan

2018

COPD

View full text Add to dashboard Cite

BackgroundEndothelial cell specific molecule-1, also called as endocan, is a dermatan sulfate proteoglycan, which is expressed by endothelial cells in alveolar walls of the lung and kidney. High endocan levels are found associated with endothelial dysfunction and inflammation. We hypothesize that endocan level is also high in COPD due to systemic inflammation and endothelial dysfunction. We aimed to investigate the expression of endocan in patients with stable COPD.Material and methodsThe study included patients with COPD and control subjects. COPD patients were classified according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 criteria. Demographics, body mass index, smoking history, and comorbidities were recorded. Endocan levels of COPD patients and controls were compared.ResultsTotally, 88 subjects (47 stable COPD patients, 41 controls) were evaluated. Endocan levels were significantly higher in COPD patients than control group (860.1±259.8 vs 647.3±316.9 pg/mL, P=0.001). There was no relationship between GOLD COPD categories and endocan levels. Also endocan levels were similar between COPD patients with or without hypoxemia.ConclusionSerum endocan level was significantly higher in patients with stable COPD. Further studies should be performed to better understand the relationship between endocan and COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum endocan levels in patients with stable COPD

Pıhtılı

Bingöl

Kıyan

2018

COPD

View full text Add to dashboard Cite

show abstract

“…The patient developed pleural dissemination and malignant pleural effusion. High VEGF levels are reported in malignant pleural effusions with different cancer origins, and VEGF signals have pathogenic roles in developing malignant pleural effusions [ [6] , [7] , [8] , [9] ]. Bevacizumab, a humanized anti-VEGF monoclonal antibody, added to a standard therapy is preferable for patients with non-small lung cancer with malignant pleural effusion [ 10 , 11 ].…”

Section: Discussionmentioning

confidence: 99%

Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum

Yanagihara

Matsumoto

Yoneda

et al. 2021

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

We describe a Case of a 74-year-old Japanese man with poorly differentiated carcinoma of the anterior mediastinum. The patient underwent anterior mediastinal tumor resection through median sternotomy. The tumor, 7.0 × 5.0 cm, had invaded surrounding tissues (pericardium, right lung, right and left brachiocephalic veins, and superior vena cava). Complete resection of the tumor was not performed. One month after the operation, the patient developed multiple pulmonary metastases, right pleural dissemination, and carcinomatous pleurisy. He was treated with lenvatinib, a novel multi-kinase inhibitor, to which the metastasis responded favorably. This case reports for the first time the clinical usefulness of lenvatinib for poorly differentiated carcinoma of the anterior mediastinum. Management of side effects by several methods, including suspending use of medication on weekends (called a weekends-off strategy), is another strong argument to continue lenvatinib administration.

show abstract

“…In 2012, a metaanalysis pooled the results of ten available studies, concluding that the diagnostic sensitivity and specificity of VEGF were 0.75 and 0.72, respectively (27). Some other studies on this topic have since been published (28)(29)(30)(31), so that an updated meta-analysis may be needed to re-assess the diagnostic accuracy of VEGF in MPE.…”

Section: Vascular Endothelial Growth Factor (Vegf) and Its Soluble Rementioning

confidence: 99%

Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review

Zhang¹,

Li²,

Lippi³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Although cytology and pleural biopsy of pleural effusion (PE) are the gold standards for diagnosing malignant pleural effusion (MPE), these tools' diagnostic accuracy is plagued by some limitations such as low sensitivity, considerable inter-observer variation and invasiveness. The assessment of PE biomarkers may hence be seen as an objective and non-invasive diagnostic alternative in MPE diagnostics. In this review, we summarize the characteristics and diagnostic accuracy of available PE biomarkers, including carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), carbohydrate antigens 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), a fragment of cytokeratin 19 (CYFRA 21-1), chitinase-like proteins (CLPs), vascular endothelial growth factor (VEGF) and its soluble receptor, endostatin, calprotectin, cancer ratio, homocysteine, apolipoprotein E (Apo-E), B7 family members, matrix metalloproteinase (MMPs) and tissue-specific inhibitors of metalloproteinases (TIMPs), reactive oxygen species modulator 1 (Romo1), tumor-associated macrophages (TAMs) and monocytes, epigenetic markers (e.g., cell-free microRNA and mRNA). We summarized the evidence from systematic review and meta-analysis for traditional tumor markers' diagnostic accuracy. According to the currently available evidence, we conclude that the traditional tumor markers have high specificity (around 0.90) but low sensitivity (around 0.50). The diagnostic accuracy of novel tumor markers needs to be validated by further studies. None of these tumor biomarkers would have sufficient diagnostic accuracy to confirm or exclude MPE when used alone. A multi-biomarker strategy, also encompassing the use of artificial intelligence algorithms, may be a valuable perspective for improving the diagnostic accuracy of MPE.

show abstract

Diagnostic Significance of Measuring Vascular Endothelial Growth Factor for the Differentiation between Malignant and Tuberculous Pleural Effusion

Cited by 9 publications

References 26 publications

Serum endocan levels in patients with stable COPD

Serum endocan levels in patients with stable COPD

Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum

Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review

Contact Info

Product

Resources

About